NIFTY 50

Here’s why Divis Laboratories is buzzing in trade

Updated : June 10, 2021 13:24:18 IST

Divis Laboratories is buzzing in trade after US signed a $1.2 billion deal for Merck’s experimental COVID drug, Molnupiravir.

Molnupiravir is an investigational oral anti-viral for COVID-19 and a deal has been signed for 1.7 million courses of the experimental COVID treatment.

Divis is the authorised manufacturer for Molnupiravir API, and is allowed to supply the API to voluntary licence partners in India.

For more details, watch the video.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you